{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-091097","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.833938+00:00","generated_at":"2026-05-17T06:13:36.347904+00:00","sec_items":["1.02"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocugen-Carisma merger terminated after Ocugen failed to secure $25M investment","bullets":["Carisma terminated Merger Agreement on Sep 16, 2025 because Ocugen obtained less than $25M in commitments for the Concurrent Investment.","Ocugen attributes difficulty to poor market conditions and the tight timeline before Carisma's Nasdaq compliance deadline of Oct 7, 2025.","Ocugen will focus on gene therapies and continue exploring other options for its regenerative cell therapy platform, including NeoCart."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-091097","json":"https://secwatch.observer/filing/0001104659-25-091097.json","markdown":"https://secwatch.observer/filing/0001104659-25-091097.md","text":"https://secwatch.observer/filing/0001104659-25-091097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925091097/0001104659-25-091097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925091097/tm2526448d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:13:36.347904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}